Benjamin F. Edwards & Company, Inc. Viking Therapeutics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 140 shares of VKTX stock, worth $4,926. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140Holding current value
$4,926% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
447Shares Held
67.7MCall Options Held
7.72MPut Options Held
3.25M-
Vanguard Group Inc Valley Forge, PA10.2MShares$358 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$212 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$133 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$114 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$110 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.7B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...